학술논문
A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings
Document Type
article
Author
Dirk Foell; Melanie Saers; Carolin Park; Ninna Brix; Mia Glerup; Christoph Kessel; Helmut Wittkowski; Claas Hinze; Lillemor Berntson; Anders Fasth; Charlotte Myrup; Ellen Nordal; Marite Rygg; Henrik Hasle; Birgitte Klug Albertsen; Troels Herlin; Dirk Holzinger; Christian Niederberger; Bernhard Schlüter
Source
Molecular and Cellular Pediatrics, Vol 10, Iss 1, Pp 1-9 (2023)
Subject
Language
English
ISSN
2194-7791
Abstract
Abstract Background Differential diagnosis in children with signs of unprovoked inflammation can be challenging. In particular, differentiating systemic juvenile idiopathic arthritis (SJIA) from other diagnoses is difficult. We have recently validated the complex of myeloid-related proteins 8/14 (MRP8/14, also known as S100A8/A9 complex or serum calprotectin) as a helpful biomarker supporting the diagnosis of SJIA. The results were subsequently confirmed with a commercial ELISA. However, further optimization of the analytical technology is important to ensure its feasibility for large-scale use in routine laboratory settings. Methods To evaluate the accuracy in identifying children with SJIA, the performance of a particle-enhanced immuno-turbidimetric assay for serum calprotectin (sCAL turbo) on an automated laboratory instrument was analyzed. Samples from 615 children were available with the diagnoses SJIA (n = 99), non-systemic JIA (n = 169), infections (n = 51), other inflammatory diseases (n = 126), and acute lymphoblastic leukemia (ALL, n = 147). In addition, samples from 23 healthy controls were included. Results The sCAL turbo assay correlated well with the MRP8/14 ELISA used in previous validation studies (r = 0.99, p